Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
Unlock the editor’s digestion free
FT editor Roula Khalaf, chooses his favorite stories in this weekly newsletter.
Novo Nordid, batching obesity medicines, reduce the market share, reduce market share, reduce market share and a leap with a decrease in exchange price and stock price.
The shares in the pharmacy fell more than 50 percent in the last 12 months, so lose one’s crown After reaching $ 650 billion last year, Europe is the largest list.
Investors, obesity and diabetes are worried that the United States has lost its place for the US opponent Eli Lilly and the next generation drugs in the pipeline are disappointed with the results of the courts.
“Given the last market Challenges, a decrease in stock price and Novo Nordisk Foundation, Novo Nordisk Council and Lars Frugaard Jørgensen, a leader’s initiative and the best interest of shareholders, “said Novo.
Last week, the company blamed the rapid expansion of replica medicines in the United States, cut off the company’s sales and profit forecasts. These cheaper alternatives – sold by the so-called combination pharmacies – were temporarily allowed when there is a lack of medicine.
Novo The increase in sales for this year is expected to be 13-21 percent this year, compared to 16-24 percent earlier. Compared to 16-24%, it forecasts an increase in growth by 16-24 percent compared to 16 to 24 percent.
Jørgensen has been for eight years, for eight years, during this period, the stock price has increased three times, with the first wave of effective obesity medications, with Wegovy and ozempic products first.
A statement on Friday, Novo noted the concern on the company’s share price on “Since 2024.” The company’s shares decreased by 21 percent in the late December, which was followed by a prosecuted obesity drug Cagrisema missed his target in late scene clinical testing.
Novo said he would give an announcement about the “over time” in search of a new chief executive. Jørgensen would continue as a period of time to provide a smooth transition.
Novo Nordisk Foundation, which owns the company via the Novo Holding, increases the representation on the board. LARS Rerien Sørensen, Department of Foundation, will immediately begin to participate in the meetings.
Jørgensen said he produced with the “results” with his colleagues, “he said,” he said to change serious chronic diseases every day ”
Shares in Novoda followed the announcement, 4.4 percent were reduced.
Nova’s chairman Helge Lund is also the chairman of the UK oil Major BP, which faces pressure on the Great activist from the Elliott Manager of the US Hedge Foundation.
